With Pfizer sale in the rearview, Biohaven veers toward Kv7 platform following late-stage trial fails, delays

Hours after Pfizer officially closed its buyout of Biohaven and its migraine program on Monday, CEO of the biotech Vlad Coric swapped his dealmaking hat for that of a salesman. To hear him tell it, the company that had elevated from a $176.1 million IPO in 2017 to raking in $11.6 billion from the Pfizer sale was Biohaven 1.0.